Taking statins to lower cholesterol? New guidelines provide opportunity to discuss options with your doctor

February 4, 2014

Clinicians and patients should use shared decision-making to select individualized treatments based on the new guidelines to prevent cardiovascular disease, according to a commentary by three Mayo Clinic physicians published in this week's Journal of the American Medical Association.

Shared decision-making is a collaborative process that allows and their clinicians to make health care decisions together, taking into account the best scientific evidence available, as well as the patient's values and preferences.

In 2013, the American College of Cardiology and the American Heart Association issued new cholesterol guidelines, replacing previous guidelines that had been in place for more than a decade. The new guidelines recommend that caregivers prescribe statins to healthy patients if their 10-year is 7.5 percent or higher.

"The new cholesterol guidelines are a major improvement from the old ones, which lacked scientific rigor," says primary author Victor Montori, M.D., Mayo Clinic endocrinologist and lead researcher in the Knowledge and Evaluation Research Unit. "The new are based upon calculating a patient's 10-year cardiovascular risk and prescribing proven cholesterol-lowering drugs—statins—if that risk is high."

However, Dr. Montori cautions that the risk threshold established by the guideline panel is somewhat arbitrary. Instead he recommends that patients and their clinicians use a decision-making tool to discuss the risks and benefits of treatment with statins.

"Rather than routinely prescribing statins to the millions of adults who have at least a 7.5 percent risk of having a heart attack or stroke within 10 years, there is an opportunity for clinicians and patients to discuss the potential benefits, harm and burdens of statins in order to arrive at a choice that reflects the existing research and the values and context of each patient," he says.

"We're creating a much more sophisticated, patient-centered practice of medicine in which we move the decision-making from the scientist to the patient who is going to experience the consequences of these treatments and the burdens of these interventions," Dr. Montori explains. "Decision-making tools can democratize this approach and put it in the hands of millions of Americans who have their own goals front and center in the decision-making process."

Explore further: Should everyone over 65 take a statin?

Related Stories

Should everyone over 65 take a statin?

August 28, 2013

(HealthDay)—Men and women over 65 who are at risk for cardiovascular disease but don't have any known heart problems might benefit from cholesterol-lowering drugs, a new study suggests.

ACC/AHA publish new guideline for management of blood cholesterol

November 12, 2013

The American College of Cardiology and the American Heart Association today released a new clinical practice guideline for the treatment of blood cholesterol in people at high risk for cardiovascular diseases caused by atherosclerosis, ...

Recommended for you

No new heart muscle cells in mice after the newborn period

November 5, 2015

A new study from Sweden's Karolinska Institutet shows that new heart muscle cells in mice are mainly formed directly after birth. After the neonatal period the number of heart muscle cells does not change, and A new study ...

Nanotechnology could spur new heart treatment

October 29, 2015

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.